Measuring Adverse Event Burden in Myasthenia Gravis: Retrospective Validation of the Adverse Event Unit With Randomized Trial of Thymectomy in Myasthenia Gravis Data
Muscle & Nerve · 2025
DOI: 10.1002/mus.28447 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Muscle & Nerve, 2025. Verfasst von Michael K Hehir und 2 weiteren Autor:innen. Beteiligte Einrichtung: University of Vermont College of Medicine, Burlington, Vermont, USA. Hauptthemen laut MEDLINE: Myasthenia Gravis, Thymectomy. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction/Aims The Adverse Event Unit (AEU) is a patient and physician weighted unit that quantifies and compares adverse event (AE) burden among any neurologic treatments. A recent study demonstrated feasibility and preliminary validity of the AEU in myasthenia gravis (MG). This study evaluated feasibility of assigning AEU scores retrospectively from pre‐existing data in the randomized clinical trial of thymectomy in MG (MGTX) and quantifying AE burden differences in participants.
Methods
Serious and non‐serious AE were recorded at MGTX visits. AEU scores were assigned by matching MGTX AE to AEU categories. Total AEU score for each participant was compared to the prednisone dosage area under the curve for years 1, 2, and 3. We also compared differences in AEU scores between participants treated with prednisone and azathioprine versus those treated with prednisone alone.
Results
All 117 MGTX patients received prednisone; 32% also received azathioprine. A weak correlation between increasing prednisone exposure and total AEU score was observed at year 2 ( r = 0.19, p = 0.04) and year 3 ( r = 0.23, p = 0.01). Participants treated with azathioprine in addition to prednisone had higher AEU scores than patients treated with prednisone alone at years 1 (median AEU 19 vs. 5, p = 0.037), 2 (median AEU 23 vs. 6, p = 0.018), and 3 (median AEU 34 vs. 9, p = 0.006).
Discussion
Pre‐existing clinical trial data can be translated into AEU scores. MG patients treated with multiple immunosuppressants had the highest AEU scores, similar to our prospective trial. Future studies will compare the side effect burden of MG treatments and define clinically meaningful AEU scores.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Vermont College of Medicine, Burlington, Vermont, USA.
- University of Alabama at Birmingham, Birmingham, Alabama, USA.
- George Washington School of Medicine and Health Sciences, Washington, District of Columbia, USA.
ORCID-Profile: Michael K Hehir, Henry J Kaminski
Zitieren
APA
Hehir, M. K., Aban, I. B., & Kaminski, H. J. (2025). Measuring Adverse Event Burden in Myasthenia Gravis: Retrospective Validation of the Adverse Event Unit With Randomized Trial of Thymectomy in Myasthenia Gravis Data. Muscle & Nerve. https://doi.org/10.1002/mus.28447
Vancouver
Hehir MK, Aban IB, Kaminski HJ. Measuring Adverse Event Burden in Myasthenia Gravis: Retrospective Validation of the Adverse Event Unit With Randomized Trial of Thymectomy in Myasthenia Gravis Data. Muscle & Nerve. 2025. doi:10.1002/mus.28447
BibTeX
@article{Hehir2025,
author = {Hehir, Michael K and Aban, Inmaculada B and Kaminski, Henry J},
title = {Measuring Adverse Event Burden in Myasthenia Gravis: Retrospective Validation of the Adverse Event Unit With Randomized Trial of Thymectomy in Myasthenia Gravis Data},
journal = {Muscle & Nerve},
year = {2025},
doi = {10.1002/mus.28447}
}
EUVIMED